ReviewFrontiers in immunology2026
NAFLD-associated immune remodeling in colorectal cancer liver metastasis: mechanisms and implications for immunotherapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) affects over 30% of the global adult population and has been increasingly recognized as an adverse prognostic factor for colorectal cancer (CRC) liver metastasis (CRLM). However, the underlying immune mechanisms remain incompletely understood. This review provides a comprehensive synthesis of how NAFLD-induced lipotoxicity reshapes the hepatic immune microenvironment to create a "fertile soil" for CRC metastatic colonization. We delineate a hierarchical immunosuppressive network involving: (1) lipotoxic apoptosis of CD4+ T cells, depleting the helper T cell pool; (2) expansion and functional reinforcement of regulatory T cells (Tregs) through multiple mechanisms (IL-10/TGF-β/IL-35, CD25-mediated IL-2 competition, CTLA-4 engagement, and granzyme B/perforin production); (3) M2 polarization of tumor-associated macrophages; and (4) recruitment of myeloid-derived suppressor cells (MDSCs) via the CXCL5/CXCR2 axis, which suppress CD8+ T cell function. These processes collectively promote CD8+ T cell exhaustion (marked by PD-1, LAG-3, TIM-3 upregulation) and spatial mismatch with metastatic foci. Importantly, we discuss the emerging evidence linking NAFLD-driven immune dysregulation to reduced responsiveness to immune checkpoint inhibitors, while acknowledging the current limitations in direct clinical validation. By integrating mechanistic insights with therapeutic perspectives, this review offers new targets for risk stratification and combination immunotherapy in the growing NAFLD population. Non-alcoholic fatty liver disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.